Much of the cost of that drug being brought to market has far less to do with innovation and much more to do with regulatory approval and clinical trials. A so

Much of the cost of that drug being brought to market has far less to do with innovation and much more to do with regulatory approval and clinical trials. A solution to address that might be in the form of designed profits, where the exclusivity period is determined by the profits generated. However I'd also still like to see second and more sources, so a compulsory license during this period is also desirable, but might focus on a fixed percentage of profits. (Also contributing to paying down the public liberation fee of the work.)